Workshop on Drug Transporters in the Lungs Trinity College Dublin 23 September 2016 @ Dublin, Ireland

### Pathophysiological role of prostaglandin transporter OATP2A1/SLCO2A1 in pulmonary fibrosis Takeo Nakanishi, Ph. D. Kanazawa University

## Local Disposition of Prostaglandin (PG) E<sub>2</sub>



## **PG Metabolisms and Lung Diseases**

## PGE<sub>2</sub> is anti-fibrotic and has beneficial actions to down-regulate fibroblast metabolic functions in the lungs.

[Cancheri et al, Trends Immunol 25:40, 2006]

# Digital clubbing is noted in idiopathic pulmonary fibrosis (IPF) and lung cancer, which are associated with serum levels of transforming growth factor (TGF- $\beta$ 1).

[Schwartz et al, Textbook of respiratory medicine, 1994, Hirakata et al, Eur J Clin Invest 26:820, 1996]

Loss-of-function mutations in *SLCO2A1* causes primary hypertrophic osteoarthropathy (HPO) and digital clubbing, associated with aberrant PG metabolism. [Seifert et al, Hum Mutat 33: 660, 2012] **Normal Finger** IPD DPD **Clubbed Digits** IPD DPD

**Digital Clubbing** 

## **OATP2A1** is a PGE<sub>2</sub> Uptake Carrier

Known as a member of organic anion transporting polypeptide family (OATP2A1) encoded by SLCO2A1.

[Kanai et al, Science 268:866, 1995; Lu et al, J Clin Invest 98:1142, 1996]

Has been characterized an influx transporter for prostanoids (e.g. PGE<sub>2</sub>, PGF<sub>2α</sub>, and PGD<sub>2</sub>) with a relatively high affinity for PGE<sub>2</sub> (e.g. Km = 20 ~ 90 nM).

[Schuster Annu. Rev. Physiol 60:221, 1998]

- Facilitates PGE<sub>2</sub> metabolism by cellular uptake of prostanoids.
- Exchanges a PG with an organic anion such as lactate.

[Chan et al, Am J Physiol Renal Physiol 282:F1097, 2002]



## **Expression of OATP2A1 in the Lungs**

## **Objectives**

To clarify expression of functional OATP2A1 in the lungs

To understand its pathophysiological significance in inflammation and pulmonary fibrosis.

These study may provide us with a clue to treat a refractory pulmonary fibrosis

## Contents

## Expression of Functional OATP2A1 in the Lungs (Physiological Condition)

## In Bleomycin(BLM)-induced Fibrosis (on Day 14)

Under Acute Inflammatory Condition induced by BLM (on Day 5)

## Expression of Oapt2a1 in Mouse Lungs (DAB Staining/Light Microscopic Analysis)



EC; Endothelial Cells. AT1/2: Type1/2 Alveolar Epithelial Cells

PLOS ONE, 10: e0123895, 2015

## Expression of Oatp2a1 in Mouse Lungs (DAB Stain/Electron Microscopic Analysis)



#### PLOS ONE, 10: e0123895, 2015

### Transdiff@Feentliptadve ofyAFT2tt&TATHkeifeetCells



Pro-SPC; pro-surfactant protein C, a marker for AT2 cells.

### mRNA Expression of Transporters That Recognize PGE<sub>2</sub> in Mouse Lungs





### Establishment of Slco2a1 Global Knockout



### Genotype (PCR)



### *Phenotype* (Western Blot, Lung)



## PGE<sub>2</sub> Uptake by AT1-like Cells Derived from *Slco2a1<sup>-/-</sup>* Mice



## Expression of Microsomal PGE Synthase-1 (PTGES) in Mouse Lungs



PLOS ONE, 10: e0123895, 2015

## Expression of Prostaglandin Dehydrogenase (15-Pgdh) in Mouse Lungs



## Summary – Role of OATP2A1 in the Lung under Physiological Condition



## **Bleomycin (BLM)-induced Lung Fibrosis**

#### BLM was intratracheally (*i.t.*) injected at 1 mg/kg in PBS to;



## Alteration in Body Weight of BLMinjected Mice



## Alveoli Structure in Mice Injected with BLM (Histological Inspection/H&E Stain)

BLM or PBS (vehicle) was intratracheally injected at 1 mg/kg in PBS; H&E Stain on Day14



× 40 Wegnification

Alveolar septum became thicker. Alveoli were collapsed in more respiratory zone.

## Sirius Red Stain for Collagen Deposition in BLM-induced Lung Fibrosis



#### Alteration in mRNA Expression of Fibrosisrelated Genes between WT and Slco2a1<sup>-/-</sup> Mice



## Amount of PGE<sub>2</sub> in the Lung and BAL Fluid of BLM-injected WT and Slco2a1<sup>-/-</sup> Mice



PLOS ONE, 10: e0123895, 2015

## Analysis of 48-Eicosanoids in BAL Fluid

1	2,3-Dinor-8-iso PGF2α 13		LXA4 25 11,12-DHET			37	12-HETE		
2	6-Ke	to-PGF1α	14	LTD4		26 8.9-DH	ET	38	8-HETE
3	20-C		15	LTC/		27 HYA2		20	12 HPETE
4	6-Ke	t		Eicosai	noids Amou	int in BAL I	luid (pg/mo	use)	ETE
5	20-0	Compounds		WT			SIco2a1 <sup>-/-</sup>		DxoETE
6	ТХВ	2		No 1	No 2	No 3	No 4	No 5	ETE
7	PGF	2		NO. I	NO. 2	NO. 3	NO. 4	NO. 3	PETE
8	PGE	<b>PGE</b> <sub>2</sub>		<u>81</u>	<u>52</u>	<u>34</u>	<u>341</u>	<u>264</u>	15-EET
9	<b>1</b> 1-D			•		•	_	•	xoETE
10	15-K			9	3	3	5	8	2-EET
11	LXB	LTE <sub>4</sub>		52	N.D.	74	85	242	т
12	rGD	14,15-DHE	Т	29	44	21	N.D.	29	
		11,12-DHE	Т	17	23	16	N.D.	N.D.	GERI
		, 11-HETE		8	12	7	16	21	
				•	•=	-			
		12-HETE		87	77	107	81	135	
		N.D. = not detected							

PG: Prostaglandin, LT: Leukotriene, DHET: Dihydroxyeicosatrienoic acid, HETE: Hydroxyeicosatetraenoic acid

#### PLOS ONE, 10: e0123895, 2015

## Summary - Effect of the Absence of Slco2a1 on BLM-induced Fibrosis



- Fibrosis became more severe in SIco2a1<sup>-/-</sup> mice.
- Fibrosis-related gene expression was increased in the lung of Slco2a1<sup>-/-</sup> mice
- Only PGE<sub>2</sub> levels were increased in the alveolar lumen.

## Hypothesized Mechanism for Aggravation of Pulmonary Fibrosis in *Slco2a1<sup>-/-</sup>* Mice



## OATP2A1 in PGE<sub>2</sub> Secretion from Peritoneal Macrophages (PMφ)

#### OATP2A1 Expression in $\text{PM}\phi$







**Biochemical Pharmacol**, 98:629-638, 2015 <sup>33</sup>

## Hypothesized Role of OATP2A1 in PGE<sub>2</sub> Secretion from Peritoneal Macrophages

- Oatp2a1 was localized in the cytoplasmic domains.
  PGE<sub>2</sub> uptake by subcellular fraction including light lysosome (e.g. acidic compartment) was inhibited with OATP2A1 inhibitors.
  - PGE<sub>2</sub> was released in a Ca<sup>2+</sup>-dependent manner.



#### Biochemical Pharmacol, 98:629-638, 2015

## Conclusion

- Loss of function of OATP2A1 may cause drug-induced pulmonary fibrosis by altering distribution of PGE<sub>2</sub> and aggravating inflammation, suggesting OATP2A1 protecting the lungs, suggesting OATP2A1 as a site of druginduced pulmonary fibrosis
- Loss of function of OATP2A1 may affect pro-inflammatory cytokine release from inflammatory cells (e.g. macrophages); however, we NEED future study.

## Acknowledgements

#### Kanazawa University

School of Pharmaceutical Sciences
 Ikumi Tamai, Hisakazu Komori



Reo Mimura, Yuka Uetoko, Yoshitaka Hasegawa, Hiroaki Shimada, Tomoka Gose, Yoshinobu Nakamura, Yasuhiro Ohno, Shunsuke Kamo, Shiori Sakiyama, Rika Aotani, Shio Maruyama, Junya Shimizu, Hiroki Takashima

 School of Health Sciences Keiichi Kawai Keio University Masatoshi Tomi

#### Cancer Center Masanobu Oshima, Hiroko Oshima

#### **University of Toyama**

Ken-ichi Hosoya, Sin-ichi Akanuma

### Kumamoto University

Tomohiko Wakayama

#### Ono Pharmaceutic Co. Ltd.

Akio Nishiura Kazuyuki Hayashi



